Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Net margin
Vertex Pharmaceuticals Incorporated's net margin over the twelve months to 30 June 2026 was 35.0%, up 2.1 percentage points from fiscal 2025 (32.9%). Over the past ten years it has ranged from −53.9% (fiscal 2015) to 68.8% (fiscal 2018); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 32.9% | 37.80 |
| FY2024 | −4.86% | (41.54) |
| FY2023 | 36.7% | (0.52) |
| FY2022 | 37.2% | 6.28 |
| FY2021 | 30.9% | (12.78) |
| FY2020 | 43.7% | 15.43 |
| FY2019 | 28.3% | (40.53) |
| FY2018 | 68.8% | 58.21 |
| FY2017 | 10.6% | 17.17 |
| FY2016 | −6.58% | 47.31 |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 33.0% | (1.54) |
| Mar 2026 | 34.5% | (2.81) |
| Dec 2025 | 37.3% | 2.14 |
| Sep 2025 | 35.2% | 0.36 |
| 42 more quarters | Free account |
Against its own ten years
Low −53.9%
High 68.8%
Ten-year median
30.9%
Current reading's percentile
64
Net margin against peers
| Company | Net margin |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | 35.0% |
| ARGX argenex SE compare | 32.2% |
| RPRX Royalty Pharma PLC compare | 32.0% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 27.9% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 16.1% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.7% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| INSM Insmed, Inc. compare | −76.9% |
| MRNA Moderna, Inc. compare | −141.4% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement